ストックスクリーナーアプリを入手
0.8604
5.14%
-0.0466
Tempest Therapeutics Inc (TPST) 最新ニュース
Tempest Therapeutics, Inc. (NASDAQ:TPST) Sees Significant Decrease in Short Interest - Defense World
TPST stock rated a Sector outperform by Scotiabank - Knox Daily
Tempest gets fast track designation from FDA for amezalpat - MSN
A closer look at Tempest Therapeutics Inc (TPST)’s stock price trends - US Post News
Tempest Therapeutics, Inc. Announces U.S. Food and Drug Administration Grants Fast Track Designation to Amezalpat (TPST-1120) - Marketscreener.com
Tempest Therapeutics Inc (TPST) Shares Rise Despite Market Challenges - The News Heater
Tempest Therapeutics Says Amezalpat Receives US FDA Fast Track Status As Treatment for Liver Cancer - Marketscreener.com
Tempest Granted Fast Track Designation From The U.S. Food And Drug Administration For Amezalpat - Marketscreener.com
Tempest Granted Fast Track Designation from the U.S. Food - GlobeNewswire
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tempest Therapeutics Awards Strategic Compensation Package: Inside the 4-Year Vesting Deal - StockTitan
Analyzing Ratios: Tempest Therapeutics Inc (TPST)’s Financial Story Unveiled - The Dwinnex
A stock that deserves closer examination: Tempest Therapeutics Inc (TPST) - US Post News
Tempest Therapeutics Inc (NASDAQ: TPST) – An Analysis Is What You Need - Stocks Register
Tempest Therapeutics, Inc. (NASDAQ:TPST) Shares Acquired by Geode Capital Management LLC - Defense World
Tempest Receives Orphan Drug Designation from the U.S. Food - GlobeNewswire
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) - GlobeNewswire Inc.
Before You Sell Tempest Therapeutics Inc (NASDAQ: TPST) Shares, Here’sWhat You Need To Know. - Stocks Register
Tempest Therapeutics Inc (NASDAQ: TPST) Investors Should Be Worried About This. - Stocks Register
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges - Investing.com Canada
TPST Stock Touches 52-Week Low at $0.8 Amid Market Challenges By Investing.com - Investing.com South Africa
Thinking about buying stock in Nikola, Delcath Systems, Taysha G - GuruFocus.com
Tempest Therapeutics amends rights agreement By Investing.com - Investing.com Australia
Tempest Therapeutics amends rights agreement - Investing.com India
Tempest Therapeutics Awards Key Employee Stock Options in Strategic Compensation Move | TPST Stock News - StockTitan
Favourable Signals For Tempest Therapeutics: Numerous Insiders Acquired Stock - Yahoo Finance
Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
William Blair Has Negative Estimate for TPST FY2024 Earnings - Defense World
Research Analysts Offer Predictions for TPST FY2024 Earnings - Defense World
500: Something went wrong - Investing.com Canada
TPST Stock Plummets to 52-Week Low at $0.85 Amid Market Struggles - Investing.com
HC Wainwright Reiterates “Buy” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Reports Q3 2024 Financial Results - TipRanks
Tempest Therapeutics price target lowered to $5 from $8 at Piper Sandler - TipRanks
TPSTTempest Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tempest Therapeutics advances liver cancer drug to Phase 3 trial By Investing.com - Investing.com Canada
Tempest Therapeutics reports Q3 EPS (41c), consensus (36c) - TipRanks
Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Tempest Therapeutics advances liver cancer drug to Phase 3 trial - Investing.com India
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 - GlobeNewswire
Tempest Gets FDA Green Light for Pivotal Phase 3 Liver Cancer Drug Trial | TPST Stock | TPST Stock News - StockTitan
TPST stock touches 52-week low at $0.91 amid market challenges - Investing.com UK
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Take off with Tempest Therapeutics Inc (TPST): Get ready for trading - SETE News
Market Momentum: Tempest Therapeutics Inc (TPST) Registers a 4.39 Increase, Closing at 1.07 - The Dwinnex
TPST stock touches 52-week low at $0.92 amid market challenges By Investing.com - Investing.com South Africa
Tempest Therapeutics Inc (TPST) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
Tempest Therapeutics maintains stock target, sector outperform rating - Investing.com
Tempest Therapeutics maintains stock target, sector outperform rating By Investing.com - Investing.com South Africa
TPST stock touches 52-week low at $0.92 amid market challenges - Investing.com
Was Tempest Therapeutics Inc (TPST)’s session last reading good? - US Post News
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):